Substituted nitrogen containing spiro compounds for use in treating cognitive deficits
CA 2118212 A1 · Owner: Du Pont Merck Pharmaceutical Company · Inventors: Brittelli, David R.; Voss, Matthew E.; Abelman, Matthew M.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
There are provided novel spirocyclic compounds of formula (I) or, physiologically suitable salts thereof wherein: X and Y are, taken together to form a saturated or unsaturated carbocylic or heterocyclic first ring and the shown carbon in said ring is .alpha. to at least one additional aromatic ring or heteroaromatic ring fused to the first ring; Z is O, S, N-NH2 2 hydrogen atoms, or H , and OH; one of Het1 or Het2 is 2- 3-, or 4-pyridyl, or 2-, 4-, or 5-pyrimidinyl and the other is selected from the group including: 2-, 3-, or 4-pyridyl, 2-, 4or 5-pyrimidinyl, 2-pyrazinyl, 3- or 4-pyridazinyl 3- or 4-pyrazolyl, 2- or, 3-tetrahydrofuranyl and 3-thienyl; pharmaceutical compositions …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 15, 1993. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 15, 2013.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 15, 2015.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.